Ken Kilgore, PhD, MBA
Ken earned his undergraduate and M.S. (Cell Biology) degrees from Western Michigan University, Kalamazoo, Michigan in 1987 and 1989, respectively. In 1993, Ken obtained his Ph.D. in Cardiovascular Pharmacology at the University of Michigan followed by postdoctoral training in the Department of Pathology (University of Michigan). After completing his postdoctoral training in 1996, Ken accepted a joint research faculty appointment in the Departments of Pharmacology and Thoracic Surgery. He joined, in 1998, the Inflammation Department at Warner-Lambert/Parke-Davis (Pfizer) in Ann Arbor, Michigan. Ken left Pfizer in 2005 to join GlaxoSmithKline in Collegeville, Pennsylvania where he was Head of Translational Pharmacology for the ImmunoInflammation Center of Excellence in Drug Discovery. In 2009, Ken joined Janssen Pharmaceuticals (Johnson and Johnson), where he led the ImmunoPharmacology Group within the Immunology Therapeutic Area. In 2013, Ken established the Early Proof-of-Concept group which sought to establish non-traditional, external collaborations/alliances to rapidly progress early-stage assets. He headed this group until his departure from Janssen in 2019. Ken is an author on over 60 scientific publications and has completed his Executive MBA at St. Joseph’s University (Philadelphia, PA). In 2017, he received the Janssen Innovation Leadership Award for his work in the area of biodefense. Ken is also active in the biotechnology start-up community via his work on the MTRAC Life Sciences Innovation Hub at the University of Michigan (Ann Arbor, MI) as well as serving as an Executive-in-Residence at Princeton University. He currently resides in Berwyn, Pennsylvania with his wife and two daughters.